Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Top Cited Papers
Open Access
- 14 October 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in Protein & Cell
- Vol. 9 (1) , 33-46
Abstract
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This new antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy. Boosted by the successes of FDA-approved Adcetris® and Kadcyla®, this drug class has been rapidly growing along with about 60 ADCs currently in clinical trials. In this article, we briefly review molecular aspects of each component (the antibody, payload, and linker) of ADCs, and then mainly discuss traditional and new technologies of the conjugation and linker chemistries for successful construction of clinically effective ADCs. Current efforts in the conjugation and linker chemistries will provide greater insights into molecular design and strategies for clinically effective ADCs from medicinal chemistry and pharmacology standpoints. The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.Keywords
This publication has 64 references indexed in Scilit:
- SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLBlood, 2013
- Cathepsin B as a cancer targetExpert Opinion on Therapeutic Targets, 2013
- Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopesProceedings of the National Academy of Sciences, 2013
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsProceedings of the National Academy of Sciences of the United States of America, 2012
- Preparation of unnatural N-to-N and C-to-C protein fusionsProceedings of the National Academy of Sciences, 2012
- Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid TumorsCancer Research, 2011
- Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial TransglutaminaseAngewandte Chemie International Edition, 2010
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasNew England Journal of Medicine, 2010
- Site‐Specific Protein Labeling via Sortase‐Mediated TranspeptidationCurrent Protocols in Protein Science, 2009
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008